Haemonetics Corporation (NYSE:HAE) – Equities research analysts at Barrington Research cut their Q3 2018 EPS estimates for shares of Haemonetics Corporation in a report released on Wednesday. Barrington Research analyst M. Petusky now forecasts that the medical instruments supplier will post earnings of $0.41 per share for the quarter, down from their previous estimate of $0.45. Barrington Research currently has a “Outperform” rating and a $57.00 target price on the stock. Barrington Research also issued estimates for Haemonetics Corporation’s Q1 2019 earnings at $0.41 EPS, Q2 2019 earnings at $0.46 EPS, Q3 2019 earnings at $0.46 EPS, Q4 2019 earnings at $0.43 EPS and FY2019 earnings at $1.75 EPS.

Haemonetics Corporation (NYSE:HAE) last released its earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.48 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.41 by $0.07. Haemonetics Corporation had a net margin of 0.50% and a return on equity of 11.16%. The firm had revenue of $225.40 million during the quarter, compared to analysts’ expectations of $219.12 million. During the same period in the prior year, the company earned $0.38 EPS. The business’s quarterly revenue was up 2.3% compared to the same quarter last year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/barrington-research-equities-analysts-decrease-earnings-estimates-for-haemonetics-corporation-hae/1695735.html.

Several other research firms have also recently weighed in on HAE. Morgan Stanley boosted their price target on Haemonetics Corporation from $43.00 to $51.00 and gave the stock an “equal weight” rating in a report on Thursday. Craig Hallum reaffirmed a “hold” rating and set a $50.00 target price (up from $40.00) on shares of Haemonetics Corporation in a research report on Wednesday. Zacks Investment Research raised Haemonetics Corporation from a “hold” rating to a “buy” rating and set a $52.00 target price on the stock in a research report on Wednesday, October 25th. TheStreet raised Haemonetics Corporation from a “c” rating to a “b-” rating in a research report on Monday, August 7th. Finally, BidaskClub raised Haemonetics Corporation from a “strong sell” rating to a “sell” rating in a research report on Tuesday, August 8th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $51.33.

Shares of Haemonetics Corporation (HAE) traded down $0.40 during midday trading on Friday, hitting $54.52. 695,600 shares of the stock traded hands, compared to its average volume of 344,366. The company has a market cap of $2,900.78, a price-to-earnings ratio of 33.69, a PEG ratio of 4.11 and a beta of 0.91. The company has a quick ratio of 1.72, a current ratio of 2.17 and a debt-to-equity ratio of 0.22. Haemonetics Corporation has a one year low of $36.44 and a one year high of $55.10.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Shine Investment Advisory Services Inc. purchased a new stake in shares of Haemonetics Corporation during the second quarter worth $132,000. Riverhead Capital Management LLC boosted its stake in shares of Haemonetics Corporation by 79.3% during the second quarter. Riverhead Capital Management LLC now owns 3,407 shares of the medical instruments supplier’s stock worth $135,000 after buying an additional 1,507 shares during the period. Pacad Investment Ltd. acquired a new stake in shares of Haemonetics Corporation during the second quarter worth about $174,000. Shelton Capital Management purchased a new position in Haemonetics Corporation during the second quarter worth about $204,000. Finally, Cubist Systematic Strategies LLC purchased a new position in Haemonetics Corporation during the second quarter worth about $260,000.

Haemonetics Corporation Company Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Earnings History and Estimates for Haemonetics Corporation (NYSE:HAE)

Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.